Related Experiment Videos
New treatments for asthma: current and future aspects
1National Heart and Lung Institute (NHLI), Clinical Studies Unit, Imperial College, and Royal Brompton Hospital, London, UK. t.hansel@ic.ac.uk
Current Opinion in Pulmonary Medicine
|June 2, 2001
Summary
Inhaled beta 2-agonists and inhaled corticosteroids (ICS) are key asthma treatments. New combination inhalers and future biotechnology offer improved, personalized asthma management strategies.
Area of Science:
- Pulmonology
- Pharmacology
- Immunology
Background:
- Inhaled beta 2-agonists and inhaled corticosteroids (ICS) are primary asthma therapies.
- Adjunctive therapies like long-acting beta 2-agonists and leukotriene antagonists are more effective than increased ICS doses.
- Combined inhalers for long-acting beta 2-agonists and ICS are now clinically available.
Purpose of the Study:
- To review current and emerging asthma treatment strategies.
- To highlight advancements in inhaled corticosteroid (ICS) and beta 2-agonist therapy.
- To discuss the potential of novel biotechnological therapies for asthma.
Main Methods:
- Literature review of current asthma treatment guidelines and research.
- Analysis of the role of adjunctive therapies in asthma management.
- Exploration of emerging biotechnological targets in asthma pathophysiology.
Main Results:
- Combined inhalers offer a convenient administration method for long-acting beta 2-agonists and ICS.
- Biotechnological therapies targeting inflammatory mediators like IgE, IL-4, and IL-5 show promise.
- Future treatments may allow for personalized medicine approaches in asthma care.
Conclusions:
- Combination inhalers represent a practical advancement in asthma therapy.
- Biotechnology offers potential for targeted, individualized asthma treatments.
- Future asthma management may involve immune system modulation for allergic responses.